Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Mostrar outras versões (1)

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R
Formato:	Journal article
Idioma:	English
Publicado em:	2014

Registros relacionados

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
por: Latimer, N, et al.
Publicado em: (2014)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
por: Guerry, M, et al.
Publicado em: (2012)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
por: Flossmann, O, et al.
Publicado em: (2006)

Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
por: Michael A Paley, et al.
Publicado em: (2019-01-01)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Robson, J, et al.
Publicado em: (2017)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
por: Basu, N, et al.
Publicado em: (2014)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
por: Pearce, F, et al.
Publicado em: (2017)

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
por: Thomas Hellmark, et al.
Publicado em: (2019-03-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre
por: Fahidah Alenzi, et al.
Publicado em: (2023-09-01)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
por: Valentina Binda, et al.
Publicado em: (2021-12-01)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Alan D. Salama
Publicado em: (2020-01-01)

Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Cheng-Hua Weng, et al.
Publicado em: (2019-12-01)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
por: Robson, J, et al.
Publicado em: (2017)

Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
por: Saket Jha, et al.
Publicado em: (2019-01-01)

Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report
por: Xinyu Weng, et al.
Publicado em: (2022-03-01)

Cardiovascular and Cerebrovascular Outcomes in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis
por: Shiyu Xiao, et al.
Publicado em: (2024-01-01)

Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Christopher Maximilian Arends, et al.
Publicado em: (2020-06-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis
por: Haiting Wu, et al.
Publicado em: (2022-04-01)

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Marta Casal Moura, et al.
Publicado em: (2022-11-01)

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis
por: Daisuke Tsukui, et al.
Publicado em: (2021-01-01)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
por: Hellmich, B, et al.
Publicado em: (2007)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
por: Laura S. van Dam, et al.
Publicado em: (2020-12-01)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
por: Luqmani, R, et al.
Publicado em: (2017)

The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
por: E. N. Vorkel, et al.
Publicado em: (2024-12-01)

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Weijun Liu, et al.
Publicado em: (2024-05-01)

Recent advances in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Si-wei Tang, et al.
Publicado em: (2024-03-01)

Oral Microbiota Profile in Patients with Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Anders Esberg, et al.
Publicado em: (2022-08-01)

Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Muskan Agarwal MD, et al.
Publicado em: (2023-10-01)

A case of Sjögren syndrome and anti-neutrophil cytoplasmic antibody-associated vasculitis
por: K. Kaynar, et al.
Publicado em: (2023-07-01)

Testicular granulomatous vasculitis mimicking testicular torsion in an anti-neutrophil cytoplasmic antibody–associated vasculitis patient
por: Liye Suo, et al.
Publicado em: (2019-01-01)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
por: Naidan Zhang, MS, et al.
Publicado em: (2022-06-01)

Clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in French children
por: Salomon R, et al.
Publicado em: (2011-09-01)

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis
por: CM Wortel, et al.
Publicado em: (2025-02-01)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
por: David Massicotte-Azarniouch, et al.
Publicado em: (2024-08-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
por: Mukhtyar, C, et al.
Publicado em: (2006)

Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
por: Zhi-Ying Li, et al.
Publicado em: (2020-08-01)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
por: Moog P, et al.
Publicado em: (2015-11-01)

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
por: Despina Michailidou, et al.
Publicado em: (2022-06-01)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
por: McLaren, J, et al.
Publicado em: (2001)

Anti-neutrophil cytoplasmic antibody–associated vasculitis complicated with diffuse alveolar haemorrhage and central nervous system vasculitis
por: Takashi Nawata, et al.
Publicado em: (2021-04-01)